Mutation of the androgen receptor causes oncogenic transformation of the prostate.
暂无分享,去创建一个
Michael Ittmann | M. Ittmann | G. Buchanan | W. Tilley | Jonathan M. Harris | F. DeMayo | N. Greenberg | G. Han | Xiaoqing Yu | Norman M Greenberg | Grant Buchanan | Jonathan M Harris | Francesco J Demayo | Xiaoqing Yu | Guangzhou Han | Wayne Tilley | Guangzhou Han | Grant Buchanan
[1] S. Yeh,et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[2] Howard M. Einspahr,et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[3] E. Small,et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.
[4] R. Hodges,et al. Positional dependence of the effects of negatively charged Glu side chains on the stability of two‐stranded α‐helical coiled‐coils , 1997, Journal of peptide science : an official publication of the European Peptide Society.
[5] N. Greenberg,et al. Immunization Against Luteinizing Hormone-Releasing Hormone Fusion Proteins Does Not Decrease Prostate Cancer in the Transgenic Adenocarcinoma Mouse Prostate Model , 2003, Experimental biology and medicine.
[6] I. McEwan,et al. Role of conserved hydrophobic amino acids in androgen receptor AF-1 function. , 2003, Journal of molecular endocrinology.
[7] W. Gerald,et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. , 2004, Endocrine-related cancer.
[8] Jian Hui Wu,et al. The androgen receptor gene mutations database (ARDB): 2004 update , 2004, Human mutation.
[9] R. Matusik,et al. Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[11] G. Jenster,et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens , 1992, Journal of Steroid Biochemistry and Molecular Biology.
[12] A. Ruffion,et al. Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[13] Division of Surgery. , 1995 .
[14] Bruce M. Spiegelman,et al. Biological Control through Regulated Transcriptional Coactivators , 2004, Cell.
[15] M. Rubin,et al. Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.
[16] T. Visakorpi,et al. Androgen receptor gene and hormonal therapy failure of prostate cancer. , 1998, The American journal of pathology.
[17] E. Wilson,et al. An Androgen Receptor NH2-terminal Conserved Motif Interacts with the COOH Terminus of the Hsp70-interacting Protein (CHIP)* , 2004, Journal of Biological Chemistry.
[18] M. Vihinen,et al. Pattern of Somatic Androgen Receptor Gene Mutations in Patients with Hormone-Refractory Prostate Cancer , 2002, Laboratory Investigation.
[19] A. Amorosi,et al. Estimation of Prostate Cancer Volume by Endorectal Coil Magnetic Resonance Imaging vs. Pathologic Volume , 1999, European Urology.
[20] J Isola,et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.
[21] H. Scher,et al. Collocation of androgen receptor gene mutations in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] B. Foster,et al. Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model , 1999, Prostate Cancer and Prostatic Diseases.
[23] R. Matusik,et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. , 1994, Molecular endocrinology.
[24] N. Greenberg,et al. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype , 2004, Journal of cellular biochemistry.
[25] N. C. Price,et al. Conformational Analysis of the Androgen Receptor Amino-terminal Domain Involved in Transactivation , 2002, The Journal of Biological Chemistry.
[26] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[27] H. Scher,et al. Prostate cancer: a dynamic illness with shifting targets. , 2003, The Lancet. Oncology.
[28] B. Foster,et al. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. , 2002, Differentiation; research in biological diversity.
[29] M. Gleave,et al. Intermittent androgen suppression for prostate cancer: rationale and clinical experience , 1998, Prostate Cancer and Prostatic Diseases.
[30] B. Foster,et al. Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate Cancer* , 2001, The Journal of Biological Chemistry.
[31] C. Huggins,et al. STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .
[32] D. Peehl,et al. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. , 1999, The Journal of urology.
[33] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.
[34] Michael M Lieber,et al. Journal Review , 2003, International Society of Hair Restoration Surgery.
[35] K. Makino,et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.
[36] Tsuey-Ming Chen,et al. Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.
[37] Peter Scholz,et al. Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor , 2000, The Journal of Biological Chemistry.
[38] J. Isaacs,et al. A history of prostate cancer treatment , 2002, Nature Reviews Cancer.
[39] F. S. French,et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.
[40] G. Buchanan,et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] J. Rosen,et al. Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.
[42] H. Klocker,et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.